User profiles for Marjolein Drent

Marjolein Drent

- Verified email at ildcare.nl - Cited by 25568

marjolein drent

- Verified email at utwente.nl - Cited by 1896

An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial …

…, CR Cordeiro, V Cottin, B Crestani, M Drent… - American journal of …, 2013 - atsjournals.org
Background: In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS)
classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, …

Which factors obstruct or stimulate teacher educators to use ICT innovatively?

M Drent, M Meelissen - Computers & education, 2008 - Elsevier
This article discusses the factors which stimulate or limit the innovative use of ICT by teacher
educators in the Netherlands. Innovative use of ICT is defined as the use of ICT applications …

An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease

…, U Costabel, RM Du Bois, M Drent… - American journal of …, 2012 - atsjournals.org
Background: The clinical utility of bronchoalveolar lavage fluid (BAL) cell analysis for the
diagnosis and management of patients with interstitial lung disease (ILD) has been a subject of …

Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline

…, ES Chen, DA Culver, W Drake, M Drent… - American journal of …, 2020 - atsjournals.org
Background: The diagnosis of sarcoidosis is not standardized but is based on three major
criteria: a compatible clinical presentation, finding nonnecrotizing granulomatous inflammation …

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement

RP Baughman, M Drent, M Kavuru… - American journal of …, 2006 - atsjournals.org
Rationale: Evidence suggests that tumor necrosis factor (TNF)-α plays an important role in
the pathophysiology of sarcoidosis. Objectives: To assess the efficacy of infliximab in …

ERS clinical practice guidelines on treatment of sarcoidosis

…, D Israel-Biet, JC Grutters, M Drent… - European …, 2021 - Eur Respiratory Soc
Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on which …

Challenges of sarcoidosis and its management

M Drent, ED Crouser, J Grunewald - New England Journal of …, 2021 - Mass Medical Soc
Sarcoidosis Sarcoidosis is a lung disease of unknown cause characterized by noncaseating
granulomas; the heart and nervous system may also be involved. It is often misdiagnosed; …

[PDF][PDF] The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool

MA Judson, U Costabel, M Drent, A Wells… - … Vasc Diffuse Lung …, 2014 - researchgate.net
Introduction: A Case Control Etiology of Sarcoidosis Study (ACCESS) sarcoidosis organ
assessment instrument has been used for more than a decade to establish uniform standards …

Neurosarcoidosis: a clinical dilemma

E Hoitsma, CG Faber, M Drent, OP Sharma - The Lancet Neurology, 2004 - thelancet.com
Sarcoidosis is an inflammatory multisystem disorder of unknown cause. Practically no organ
is immune to sarcoidosis; most commonly, in up to 90% of patients, it affects the lungs. The …

Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS)

…, H Michielsen, GL Van Heck, M Drent - British journal of health …, 2004 - Wiley Online Library
Fatigue is a major problem in a wide range of diseases including sarcoidosis. However, there
is no standard measure for assessing fatigue. Therefore, the aim of the present study was …